Perrigo Company plc Increase (Decrease) in Contract with Customer, Liability
Perrigo Company plc (PRGO) reported Increase (Decrease) in Contract with Customer, Liability of $500.00 thousand for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- Perrigo Company plc increase (decrease) in contract with customer, liability for the quarter ending 2026-06-27 was $3.00M.
- Perrigo Company plc increase (decrease) in contract with customer, liability for the quarter ending 2026-03-28 was -$2.50M, a 139.06% decline year-over-year.
- Perrigo Company plc increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$1.40M.
- Perrigo Company plc increase (decrease) in contract with customer, liability for the quarter ending 2025-09-27 was -$24.20M.
- Perrigo Company plc increase (decrease) in contract with customer, liability for fiscal 2025 was -$26.20M.
- Perrigo Company plc increase (decrease) in contract with customer, liability for fiscal 2024 was -$25.60M, a 210.34% decline from fiscal 2023.
- Perrigo Company plc increase (decrease) in contract with customer, liability for fiscal 2023 was $23.20M, a 107.14% increase from fiscal 2022.
- Perrigo Company plc increase (decrease) in contract with customer, liability for fiscal 2022 was $11.20M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-27 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $500.00K 10-Q · filed 2026-08-05 | -$900.00K derived: sum of 3 quarters · filed 2026-08-05 | -$25.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | -$2.50M 10-Q · filed 2026-05-06 | -$3.90M derived: sum of 2 quarters · filed 2026-05-06 | -$28.10M derived: sum of 3 quarters · filed 2026-05-06 | -$35.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$25.60M derived: sum of 2 quarters · filed 2026-02-26 | -$32.60M derived: sum of 3 quarters · filed 2026-08-05 | -$26.20M 10-K · filed 2026-02-26 |
| 2025-09-27 | -$24.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$31.20M derived: sum of 2 quarters · filed 2026-08-05 | -$24.80M 10-Q · filed 2025-11-05 | -$52.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | -$7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$600.00K 10-Q · filed 2026-08-05 | -$28.20M derived: sum of 3 quarters · filed 2026-08-05 | -$32.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $6.40M 10-Q · filed 2026-05-06 | -$21.20M derived: sum of 2 quarters · filed 2026-05-06 | -$25.00M derived: sum of 3 quarters · filed 2026-05-06 | -$37.40M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$27.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$31.40M derived: sum of 2 quarters · filed 2026-02-26 | -$43.80M derived: sum of 3 quarters · filed 2026-02-26 | -$25.60M 10-K · filed 2026-02-26 |
| 2024-09-28 | -$3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$16.20M derived: sum of 2 quarters · filed 2025-11-05 | $2.00M 10-Q · filed 2025-11-05 | $4.70M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-29 | -$12.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.80M 10-Q · filed 2025-08-06 | $8.50M derived: sum of 3 quarters · filed 2026-02-26 | -$6.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-30 | $18.20M 10-Q · filed 2025-05-07 | $20.90M derived: sum of 2 quarters · filed 2026-02-26 | $6.30M derived: sum of 3 quarters · filed 2026-02-26 | $34.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$11.90M derived: sum of 2 quarters · filed 2026-02-26 | $16.40M derived: sum of 3 quarters · filed 2026-02-26 | $23.20M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$14.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $13.70M derived: sum of 2 quarters · filed 2024-11-06 | $20.50M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $28.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $35.10M 10-Q · filed 2024-08-02 | ||
| 2023-04-01 | $6.80M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $11.20M 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |